PharVision Advisers’s Las Vegas Sands LVS Stock Holding History

PharVision Advisers’s Portfolio LVS Stock Details LVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,682	Closed	-$630K	–	411
2025 Q4	$630K	Buy	9,682 +2,920	+43%	+$179K	0.32%	11
2025 Q3	$364K	Buy	+6,762	New	+$356K	0.2%	119
2025 Q2	–	Sell	-9,765	Closed	-$377K	–	366
2025 Q1	$377K	Buy	+9,765	New	+$431K	0.52%	49

Other funds holding LVS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

PharVision Advisers's LVS Position: Q1 2026 in Review

PharVision Advisers sold out of Las Vegas Sands (LVS) in Q1 2026, closing a stake of 9,682 shares — an estimated $630K sold.

PharVision Advisers first reported a position in LVS in Q1 2025 and held it in 3 quarters. The position peaked at $630K in Q4 2025. 759 funds tracked by Wall St. Rank hold LVS as of Q1 2026.

PharVision Advisers reported no remaining Las Vegas Sands position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 9,682 Las Vegas Sands shares in Q1 2026, an estimated $630K.
PharVision Advisers first reported a position in Las Vegas Sands in Q1 2025 and held it in 3 quarters.
PharVision Advisers's Las Vegas Sands position peaked at $630K in Q4 2025.
759 funds tracked by Wall St. Rank held Las Vegas Sands as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.